P‐Glycoprotein‐Dependent Trafficking of Nanoparticle‐Drug Conjugates
Source abstract
Abstract
P-glycoprotein (P-gp) is considered to be the most prevalent and single most important cause of multidrug-resistance (MDR) in humans. Although the protein is well known to modulate the cellular trafficking of small molecule fluorophores, antimicrobials, and up to 50% of all cytotoxic chemotherapeutics, little is known about its interactions with nanoscale drug conjugates. Here, we use P-gp substrate-conjugated gold nanorods as model drug carriers to investigate P-gp-dependent cellular trafficking of nanoparticles.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Drug Transport and Resistance Mechanisms · Nanoparticle-Based Drug Delivery · Nanocluster Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Laser Dynamics Laboratory Department of Chemistry and Biochemistry Georgia Institute of Technology 901 Atlantic Drive NW Atlanta GA 30332–0400 USA
Petit Institute for Bioengineering and Biosciences Department of Chemistry and Biochemistry Georgia Institute of Technology 315 Ferst Drive NW Atlanta GA 30332–0230 USA
References (50)
Show source-provided references
1. 10.1126/science.116875010.1126/science.1168750 ↗
2. 10.1093/jnci/95.4.25510.1093/jnci/95.4.255 ↗
3. 10.1073/pnas.101464110810.1073/pnas.1014641108 ↗
4. 10.1073/pnas.081332710610.1073/pnas.0813327106 ↗
5. 10.1073/pnas.121130911010.1073/pnas.1211309110 ↗
6. 10.1021/ja801631c10.1021/ja801631c ↗
7. 10.1021/ja108846h10.1021/ja108846h ↗
8. 10.1002/smll.20070021710.1002/smll.200700217 ↗
9. 10.1056/NEJMra091227310.1056/NEJMra0912273 ↗
10. 10.1021/ja307589n10.1021/ja307589n ↗
11. 10.1021/ar800035u10.1021/ar800035u ↗
12. 10.1039/C1CS15237H10.1039/C1CS15237H ↗
13. 10.1158/1078-0432.CCR-10-097810.1158/1078-0432.CCR-10-0978 ↗
14. US National Institutes of Health. Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck.http://clinicaltrials.gov/ct2/show/NCT00848042(accessed April 8 2011).
15. 10.1021/ac901838910.1021/ac9018389 ↗
16. 10.1021/ac300405510.1021/ac3004055 ↗
17. 10.1002/smll.20120033310.1002/smll.201200333 ↗
18. 10.1128/AAC.47.3.1047-1051.200310.1128/AAC.47.3.1047-1051.2003 ↗
19. 10.1128/AAC.49.6.2372-2377.200510.1128/AAC.49.6.2372-2377.2005 ↗
20. 10.2174/156801202335502710.2174/1568012023355027 ↗
21. 10.7164/antibiotics.54.66410.7164/antibiotics.54.664 ↗
22. 10.7164/antibiotics.57.51810.7164/antibiotics.57.518 ↗
23. 10.1021/mp050087110.1021/mp0500871 ↗
24. 10.1016/j.canlet.2008.04.02610.1016/j.canlet.2008.04.026 ↗
25. 10.1021/bc900221210.1021/bc9002212 ↗
26. 10.1021/ar200312210.1021/ar2003122 ↗
27. 10.1021/bc300158k10.1021/bc300158k ↗
28. 10.1093/jac/dkg22510.1093/jac/dkg225 ↗
29. Bryskier A. J. · 1993
30. 10.1007/978-3-0348-8105-010.1007/978-3-0348-8105-0 ↗
31. Carlier M. B. · Int. J. Tissue React.‐Exp. Clin. Asp. · 1994 · 16 · 211
32. Iwahashi T. · Cancer Res. · 1993 · 53 · 5475
33. Rao U. S. · Mol. Pharmacol. · 1994 · 45 · 77310.1016/S0026-895X(25)10165-X ↗
34. Vazifeh D. · Antimicrob. Agents Chemother. · 1998 · 42 · 194410.1128/AAC.42.8.1944 ↗
35. 10.1038/sj.onc.120694810.1038/sj.onc.1206948 ↗
36. 10.1016/S1043-6618(03)00158-010.1016/S1043-6618(03)00158-0 ↗
37. 10.1201/b11516-2310.1201/b11516-23 ↗
38. 10.1021/bc200386m10.1021/bc200386m ↗
39. 10.1021/ja401114510.1021/ja4011145 ↗
40. 10.1021/nl302758610.1021/nl3027586 ↗
41. 10.1039/c0cs00180e10.1039/c0cs00180e ↗
42. 10.1016/j.biocel.2011.12.00910.1016/j.biocel.2011.12.009 ↗
43. 10.1002/jps.2078010.1002/jps.20780 ↗
44. 10.1091/mbc.E02-11-070410.1091/mbc.E02-11-0704 ↗
45. 10.1074/jbc.274.11.697910.1074/jbc.274.11.6979 ↗
46. 10.1016/S0021-9258(18)43886-010.1016/S0021-9258(18)43886-0 ↗
47. 10.1016/S0092-8674(00)81370-710.1016/S0092-8674(00)81370-7 ↗
48. 10.1038/nchembio.7910.1038/nchembio.79 ↗
49. 10.4161/auto.647710.4161/auto.6477 ↗
50. 10.1021/nn404792510.1021/nn4047925 ↗